Latest revenue
$0
as of 2025-09-30
Latest net income
$-2.8M
as of 2025-09-30
Net margin
—
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AZTR is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.5M
- Enterprise value
- $-6.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.33×
- Dividend yield
- 0.0%
- 52-wk high
- $1.40
- 52-wk low
- $0.10
- Beta
- —
- Shares out
- 16.2M
5-year trend
What this company does
Item 1. Business Background Azitra, Inc. was formed as a Delaware corporation on January 2, 2014 as a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Since our formation, we have built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen our library of strains for drug like molecules. The platform also utilizes a licensed genetic…
AI summary unavailable — showing raw filing excerpt
Generated from AZTR's filing dated 2026-02-27
Key risks
Item 8. Financial Statements and Supplementary Data Index to Financial Statements Page Report of Independent Registered Public Accounting Firm (PCAOB ID Number 606) F-1 Balance Sheets at December 31, 2025 and 2024 F-2 Statements of Operations for the years ended December 31, 2025 and 2024 F-4 Statements of Changes in Stockholders' Equity (Deficit) for the years ended December 31, 2025 and 2024 F-5 Statements of Cash Flows for the years ended December 31, 2025 and 2024 F-6 Notes to the Financial Statements F-8 80 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Azitra, Inc. Branford, CT Opinion on the Financial Statements We have audited…
AI summary unavailable — showing raw filing excerpt
Generated from AZTR's filing dated 2026-02-27
Profitability
Operating margin
-146468.5%
13092.3%Net margin
-119566.6%
7169.1%Return on equity
-288.2%
83.1%Return on assets
-218.0%
78.9%Leverage
Debt / equity
0.32×
10.5%Long-term debt / equity
0.00×
100.0%Debt / assets
24.4%
8.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-3.9M | -28.0% | — |
Q4 2025 2025-12-31 | — | — | $-2.2M | +6.7% | — |
Q3 2025 2025-09-30 | $0 | — | $-2.8M | -173.9% | — |
Q2 2025 2025-06-30 | $0 | -100.0% | $-2.9M | -9.8% | — |
Q1 2025 2025-03-31 | — | — | $-3.1M | -4.6% | — |
Q4 2024 2024-12-31 | $0 | — | $-2.4M | — | — |
Q3 2024 2024-09-30 | $0 | -100.0% | $-1.0M | +48.1% | — |
Q2 2024 2024-06-30 | $7.5K | -95.6% | $-2.6M | +40.6% | -35093.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AZTR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AZTR
Institutional value
$7.5K
Total shares held
31.9K
Distinct holders
2
-6 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 30.2K | $7.1K | +29.2K (+2926.6%) | Added |
| 2 | CITIGROUP INC | 1.7K | $399 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AZTR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.